Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 2

Conditions

Carcinoma, Non-Small-Cell Lung 205Breast Neoplasms 187Neoplasms 167Leukemia, Myeloid, Acute 164Multiple Myeloma 157Lymphoma 120Melanoma 117Neoplasm Metastasis 114Lymphoma, Non-Hodgkin 110Prostatic Neoplasms 109Leukemia 107Colorectal Neoplasms 96Recurrence 91Leukemia, Lymphocytic, Chronic, B-Cell 90Pancreatic Neoplasms 85Ovarian Neoplasms 85Myelodysplastic Syndromes 83Lung Neoplasms 83Lymphoma, Follicular 78Glioblastoma 78Precursor Cell Lymphoblastic Leukemia-Lymphoma 77Lymphoma, Large B-Cell, Diffuse 77Hodgkin Disease 69Lymphoma, Mantle-Cell 65Carcinoma, Renal Cell 62Brain Neoplasms 56Small Cell Lung Carcinoma 55Squamous Cell Carcinoma of Head and Neck 54Triple Negative Breast Neoplasms 52Sarcoma 52

Interventions

ruxolitinib 2sonidegib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Has results × Thrombocytosis × Clear all
NCT01787552 2020-04-15

A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF

Novartis

Phase 1/2 Completed
50 enrolled 23 charts
Myeloid

Blood Coagulation Disorders, Blood Platelet Disorders, Bone Marrow Diseases, Hematologic Diseases, Hemorrhagic Disorders, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Thrombocytosis, Primary Myelofibrosis

NCT00509899 2018-03-12

Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis

Incyte Corporation

Phase 1/2 Completed
154 enrolled 26 charts
Myeloid

Polycythemia Vera, Thrombocytosis, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡